糖心原创

Contact

• workRoom CS6 The Medical School, Floor C
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• work0115 82 30084
• fax0115 82 30081
• Nick.Holliday@nottingham.ac.uk

Biography

Following undergraduate studies at the University of Cambridge (BA St John's College, 1994), Nick Holliday obtained his PhD from King's College London (1998), supported by an AJ Clark PhD studentship from the British Pharmacological Society. During subsequent postdoctoral work in London, his interests in peptide messengers regulating appetite and metabolism became focused on molecular mechanisms underlying the signalling and regulation of their receptors. Nick was awarded a independent RCUK fellowship at the 糖心原创 in 2006, followed by Lecturer (2011) and Associate Professor (2013) positions. While at Nottingham, Nick's group has been funded by the MRC, charity, the Brazilian CAPES drug discovery program and industrial collaborations, and in 2011 he was awarded the from the British Pharmacological Society. He has also been actively involved in public engagement, including an arts crossover project to explain the use of imaging in pharmacology (""), funded by the Wellcome Trust.

Expertise Summary

GPCRs for peptides such as neuropeptide Y, gastrin releasing peptide and ghrelin, and nutrients such as free fatty acids, are implicated in the control of appetite, body weight and insulin secretion. They provide new drug targets to treat diabetes and obesity, and as such an understanding of the cellular mechanisms that regulate receptor function is crucial when considering long-term treatment of these conditions

Our group focuses on understanding the mechanisms underlying the signalling and intracellular trafficking of these GPCRs, and developing methods to assess ligand pharmacology for these processes. We have particular expertise in high content imaging and fluorescence / luminescence complementation approaches to develop GPCR protein-protein interaction assays, with the aim to study pharmacology at the level of individual signalling complexes and so better understand the effects of GPCR dimers and ligands which are signalling biased. Recently (in collaboration with Tom Bellamy), we are developing light (optogenetic) and "designer drug" activated receptors to explore spatiotemporal signalling in both model cell systems and astrocytes.

Group members:

CAPES Drug Discovery program: Dr Corado Pedebos

PhD students: Rachel Richardson, Laura Humphrys, Jess Carpenter, Saori Mukaida, Aaron Horsey, Matt Gibbs, Nicola Dijon, Desi Nesheva

Research Interests

Signalling bias in peptide and dopamine receptors

Mechanisms of GPCR internalisation and intracellular trafficking defined through high content imaging

Allosteric interactions in peptide receptor homo and heterodimers

Optogenetic and chemogenetic stimulation of GPCR signalling

Research Expertise

GPCR pharmacology (binding and signalling assays)

High content confocal imaging and analysis

Fluorescence and luminescence complementation to detect protein interactions

Optogenetic and designer G protein coupled receptors

Teaching Summary

Main responsibilities:

Module Convenor

B31ESP - Essential Skills for Phamacists (Year 1, MPharm 40 credit)

C12PBT - Pharmacological Basis of Therapeutics (year 2, BSc, 20 credit)

A13GPD - GPCR polymorphisms, disease and personalised medicine (Year 3, BMedSci)

B33PPM - GPCR based personalised medicine (Year 3, MPharm)

Key Contributor

B34FME - Future Medicines (MPharm year 4)

Senior Tutor for the MPharm degree

Selected Publications

• SYKES DA, MOORE H, STOTT LA, HOLLIDAY ND, JAVITCH JA, LANE JR and CHARLTON SJ, 2017. Nature Communications. (In Press.)
• KILPATRICK LE, HUMPHRYS LJ and HOLLIDAY ND, 2015. Molecular pharmacology. 87(4), 718-32
• WONG, KELVIN, BRIDDON, STEPHEN J., HOLLIDAY, NICHOLAS D. and KERR, IAN D., 2016. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. 1863(1), 19-29
• LIU M, MOUNTFORD SJ, RICHARDSON RR, GROENEN M, , HOLLIDAY ND and THOMPSON PE, 2016. J Med Chem. 59(13), 6059-6069

• View all publications

• FREITAS ACN, PEIGNEUR S, MACEDO FHP, MENEZES-FILHO JE, MILLNS P, MEDEIROS LF, ARRUDA MA, CRUZ J, HOLLIDAY ND, TYTGAT J, HATHWAY G and DE LIMA ME, 2018. Toxins. 10(1),
• SYKES DA, MOORE H, STOTT LA, HOLLIDAY ND, JAVITCH JA, LANE JR and CHARLTON SJ, 2017. Nature Communications. (In Press.)
• WONG, KELVIN, BRIDDON, STEPHEN J., HOLLIDAY, NICHOLAS D. and KERR, IAN D., 2016. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. 1863(1), 19-29
• STOTT, LISA A., HALL, DAVID A. and HOLLIDAY, NICHOLAS D., 2016. BIOCHEMICAL PHARMACOLOGY. 101, 1-12
• LIU M, MOUNTFORD SJ, RICHARDSON RR, GROENEN M, , HOLLIDAY ND and THOMPSON PE, 2016. J Med Chem. 59(13), 6059-6069
• LIU, MENGJIE, RICHARDSON, RACHEL R., MOUNTFORD, SIMON J., ZHANG, LEI, TEMPONE, MATHEUS H., HERZOG, HERBERT, HOLLIDAY, NICHOLAS D. and THOMPSON, PHILIP E., 2016. BIOCONJUGATE CHEMISTRY. 27(9), 2166-2175
• NORTHFIELD, SUSAN E., MOUNTFORD, SIMON J., WIELENS, JEROME, LIU, MENGJIE, ZHANG, LEI, HERZOG, HERBERT, HOLLIDAY, NICHOLAS D., SCANLON, MARTIN J., PARKER, MICHAEL W., CHALMERS, DAVID K. and THOMPSON, PHILIP E., 2015. AUSTRALIAN JOURNAL OF CHEMISTRY. 68(9), 1365-1372
• KILPATRICK LE, HUMPHRYS LJ and HOLLIDAY ND, 2015. Molecular pharmacology. 87(4), 718-32
• VALENTIN-HANSEN L, FRIMURER TM, MOKROSINSKI J, HOLLIDAY ND and SCHWARTZ TW, 2015. The Journal of biological chemistry. 290(40), 24495-508
• ALQAHTANI F, MAHDAVI J, WHELDON LM, VASSEY M, PIRINCCIOGLU N, ROYER P, QARANI SM, MORROLL S, STOOF J, HOLLIDAY ND, TEO SY, OLDFIELD NJ, WOOLDRIDGE KG and ALA'ALDEEN DAA, 2014. Open biology. 4(10),
• MOUNTFORD SJ, LIU M, ZHANG L, GROENEN M, HERZOG H, HOLLIDAY ND and THOMPSON PE, 2014. Organic & biomolecular chemistry. 12(20), 3271-81
• ENGELSTOFT MS, NORN C, HAUGE M, HOLLIDAY ND, ELSTER L, LEHMANN J, JONES RM, FRIMURER TM and SCHWARTZ TW, 2014. British journal of pharmacology. 171(24), 5774-89
• SIVERTSEN, B., HOLLIDAY, N., MADSEN, A. N. and HOLST, B., 2013. BRITISH JOURNAL OF PHARMACOLOGY. 170(7), 1349-1362
• HOLLIDAY ND, WATSON SJ and BROWN AJH, 2012. Frontiers in Endocrinology: Frontiers in Molecular and Structural Endocrinology. 2,
• WATSON, S-J., BROWN, A.J.H. and HOLLIDAY, N.D., 2012. Molecular Pharmacology. 81(5), 631-642
• KILPATRICK, L.E., BRIDDON, S.J. and HOLLIDAY, N.D., 2012. Biochemica Biophysica Acta: Molecular Cell Research. 1823(6), 1068-1081
• HANSEN, L.V., GROENEN, M., NYGAARD, R., FRIMURER, T.M., HOLLIDAY, N.D. and SCHWARTZ, T.W., 2012. Journal of Biological Chemistry. 287, 31973-31982
• KILPATRICK LE and HOLLIDAY ND, 2012. Methods in molecular biology (clifton, n.j.). 897, 109-38
• HAIDER, A.J., BRIGGS, D., SELF, T.J., CHILVERS, H.L., HOLLIDAY, N.D. and KERR, I.D., 2011. PLoS ONE. 6(10), e25818
• EVANS, E.L., SAXTON, J., SHELTON, S.J., BEGITT, A., HOLLIDAY, N.D., HIPSKIND, R.A. and SHAW, P.E., 2011. Nucleic Acids Research. 39(15), 6390-6402
• SIVERTSEN, B, LANG, MJ, FRIMURER, TM, HOLLIDAY, ND, BACH, A, ELS, S, ENGELSTOFT, MS, PETERSEN, PS, MADSEN, AN, SCHWARTZ, TW, BECK-SICKINGER, AG and HOLST, B, 2011. Journal Of Biological Chemistry. 286(23), 20845-20860
• KILPATRICK, L.E., BRIDDON, S.J., HILL, S.J. and HOLLIDAY, N.D., 2010. British Journal of Pharmacology. 160(4), 892-906
• ROSE, RH, BRIDDON, SJ and HOLLIDAY, ND, 2010. British Journal of Pharmacology. 738-750
• JORGENSEN, R., HOLLIDAY, N.D., HANSEN, J.L., VRECL, M., HEDING, A., SCHWARTZ, T.W. and ELLING, C.E., 2008. Molecular Pharmacology. 73(2), 349-358
• HOLLIDAY, N.D., TOUGH, I.R. and COX, H.M., 2007. British Journal of Pharmacology. 152(1), 132-140
• HOLLIDAY, NICHOLAS D, HOLST, BIRGITTE, RODIONOVA, ELENA A, SCHWARTZ, THUE W and COX, HELEN M, 2007. Molecular Endocrinology. 21(12), 3100-12
• TOUGH, I.R., HOLLIDAY, N.D. and COX, H.M, 2006. Journal of Pharmacology and Experimental Therapeutics. 319(1), 20-30
• HOLLIDAY, N.D., LAM, C-W., TOUGH, I.R. and COX, H.M, 2005. Molecular Pharmacology. 67(3), 655-664
• HOLST, B., HOLLIDAY, N.D., BACH, A., ELLING, C.E., COX, H.M. and SCHWARTZ, T.W, 2004. Journal of Biological Chemistry. 279(51), 53806-53817
• HOLLIDAY,N.D, MICHEL,M.C and COX,H.M, 2004. Neuropeptide Y receptors and their signalling. In: MICHEL, MC, ed., Neuropeptide Y and related peptides Springer-Verlag. 45-73
• HOLLIDAY, N.D. and COX, H.M, 2003. British Journal of Pharmacology. 139(3), 501-12
• COX, H.M, TOUGH, I.R, ZANDVLIET, D.W.J. and HOLLIDAY, N.D, 2001. British Journal of Pharmacology. 132(1), 345-53
• HOLLIDAY, N D, POLLOCK, E L, TOUGH, I R and COX, H M, 2000. Canadian Journal of Physiology and Pharmacology. 78(2), 126-33
• HOLLIDAY, N D and COX, H M, 1999. British Journal of Pharmacology. 126(1), 269-79
• HOLLIDAY, N D, TOUGH, I R and COX, H M, 1997. Naunyn-Schmiedeberg's Archives of Pharmacology. 355(2), 183-9
• HOLLIDAY, N D and COX, H M, 1996. The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor. British Journal of Pharmacology. 119(2), 321-9
• HOLLIDAY, N, BALBI, D, PANCE, A and ALLEN, J M, 1995. Biochemical Society Transactions. 23(2), 226S
• PANCE, A, BALBI, D, HOLLIDAY, N and ALLEN, J M, 1995. Biochemical Society Transactions. 23(1), 47S